BAKER BROS. ADVISORS LP Q3 2016 Filing
Filed November 14, 2016
Portfolio Value
$11.0B
Holdings
134
Report Date
Q3 2016
Filing Type
13F-HR
All Holdings (134 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | 44,100,294 | $2.4T | 21614.09% | |
| 2 | INCYIncyte Corporation | 23,498,898 | $2.2T | 20106.40% | |
| 3 | ABBVAbbVie Inc. | 14,343,358 | $904.6B | 8209.09% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 25,819,768 | $821.3B | 7453.11% | |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | 6,543,295 | $801.8B | 7276.05% | |
| 6 | —Incyte Corporation Notes 1.25% 11/15/2020 144A | 274,500,000 | $531.2B | 4820.76% | |
| 7 | —Incyte Corporation Notes 0.375% 11/15/2018 144A | 259,000,000 | $491.3B | 4458.69% | |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 4,806,483 | $444.7B | 4035.38% | |
| 9 | —Genomic Health, Inc. | 13,770,302 | $398.2B | 3613.79% | |
| 10 | —DBV Technologies S.A. | 5,509,560 | $200.2B | 1816.36% | |
| 11 | —Aquinox Pharmaceuticals, Inc. | 10,536,092 | $140.8B | 1277.34% | |
| 12 | —BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017 | 22,379,000 | $101.4B | 920.20% | |
| 13 | —Bellicum Pharmaceuticals, Inc. | 4,865,647 | $96.8B | 878.64% | |
| 14 | CERSCerus Corporation | 13,053,275 | $81.1B | 735.59% | |
| 15 | —Spark Therapeutics, Inc. | 1,318,341 | $79.2B | 718.52% | |
| 16 | —Acorda Therapeutics, Inc. | 3,661,082 | $76.4B | 693.68% | |
| 17 | —Clovis Oncology, Inc. 2.5% 9/15/2021 | 72,758,000 | $69.1B | 627.36% | |
| 18 | AMRNAmarin Corporation plc | 20,630,477 | $65.8B | 597.20% | |
| 19 | EX9Exelixis, Inc. | 4,929,494 | $63.0B | 572.13% | |
| 20 | —Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021 | 77,083,000 | $62.8B | 570.15% | |
| 21 | ONCBeiGene, Ltd. | 1,912,680 | $58.9B | 534.76% | |
| 22 | NVTA1EURInvitae Corporation | 6,554,967 | $57.4B | 521.07% | |
| 23 | HRTXHeron Therapeutics, Inc. | 2,857,250 | $49.2B | 446.74% | |
| 24 | BCRXBioCryst Pharmaceuticals, Inc. | 10,963,944 | $48.4B | 438.76% | |
| 25 | NBIXNeurocrine Biosciences, Inc. | 895,422 | $45.3B | 411.47% | |
| 26 | —Advanced Accelerator Applications S.A. | 1,029,247 | $39.2B | 355.66% | |
| 27 | —Versartis, Inc. | 2,134,247 | $26.1B | 237.25% | |
| 28 | —Progenics Pharmaceuticals, Inc. | 3,650,808 | $23.1B | 209.71% | |
| 29 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $22.8B | 207.28% | |
| 30 | ARRYEURArray BioPharma Inc. | 3,310,666 | $22.3B | 202.79% | |
| 31 | XNCRXencor, Inc. | 872,072 | $21.4B | 193.80% | |
| 32 | HALOHalozyme Therapeutics, Inc. | 1,731,057 | $20.9B | 189.76% | |
| 33 | —Achillion Pharmaceuticals, Inc. | 2,475,515 | $20.1B | 181.96% | |
| 34 | —bluebird bio, Inc. | 293,943 | $19.9B | 180.79% | |
| 35 | MRUSMerus N.V. | 1,160,014 | $19.4B | 176.32% | |
| 36 | GBYSangamo BioSciences, Inc. | 4,055,876 | $18.8B | 170.41% | |
| 37 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $18.1B | 164.04% | |
| 38 | —Idera Pharmaceuticals, Inc. | 7,014,015 | $18.0B | 162.94% | |
| 39 | —Derma Sciences, Inc. | 3,752,390 | $17.5B | 159.02% | |
| 40 | —Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019 | 26,517,000 | $17.4B | 158.19% | |
| 41 | GLPGGalapagos NV | 259,894 | $16.8B | 152.50% | |
| 42 | TGTXTG Therapeutics, Inc. | 2,003,991 | $15.5B | 140.75% | |
| 43 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $15.0B | 136.11% | |
| 44 | ASNDAscendis Pharma A/S | 745,521 | $15.0B | 135.98% | |
| 45 | —BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018 | 12,228,000 | $14.6B | 132.76% | |
| 46 | ARWRArrowhead Pharmaceuticals, Inc. | 1,856,967 | $13.6B | 123.86% | |
| 47 | —Vitae Pharmaceuticals, Inc. | 637,597 | $13.3B | 121.04% | |
| 48 | ALKSAlkermes plc | 250,251 | $11.8B | 106.80% | |
| 49 | —Zogenix, Inc. | 1,000,000 | $11.4B | 103.72% | |
| 50 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $11.3B | 102.52% | |
| 51 | —Dermira, Inc. | 326,428 | $11.0B | 100.18% | |
| 52 | AGIOAgios Pharmaceuticals, Inc. | 207,915 | $11.0B | 99.66% | |
| 53 | MGNXMacroGenics, Inc. | 363,676 | $10.9B | 98.71% | |
| 54 | —Aimmune Therapeutics, Inc. | 673,908 | $10.1B | 91.73% | |
| 55 | —ContraFect Corporation | 4,045,876 | $10.0B | 91.05% | |
| 56 | —Dimension Therapeutics, Inc. | 1,251,881 | $10.0B | 90.77% | |
| 57 | SG7Sage Therapeutics, Inc. | 208,328 | $9.6B | 87.06% | |
| 58 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $9.3B | 84.25% | |
| 59 | IMGNEURImmunoGen, Inc. | 3,015,353 | $8.1B | 73.33% | |
| 60 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $7.5B | 67.97% | |
| 61 | —Alder BioPharmaceuticals, Inc. | 217,328 | $7.1B | 64.63% | |
| 62 | RAREUltragenyx Pharmaceutical Inc. | 100,000 | $7.1B | 64.37% | |
| 63 | —Inotek Pharmaceuticals Corporation Notes 5.75% 8/1/2021 | 5,000,000 | $6.7B | 60.87% | |
| 64 | TREURTrillium Therapeutics Inc. | 413,697 | $6.1B | 55.54% | |
| 65 | IM8NInsmed Incorporated | 400,000 | $5.8B | 52.70% | |
| 66 | —Alcobra Ltd. | 2,336,359 | $5.8B | 52.37% | |
| 67 | PRQRProQR Therapeutics N.V. | 860,464 | $5.7B | 52.08% | |
| 68 | —NeuroDerm Ltd. | 305,000 | $5.6B | 51.17% | |
| 69 | CPRXCatalyst Pharmaceuticals, Inc. | 5,102,153 | $5.6B | 50.46% | |
| 70 | NTRANatera, Inc. | 450,000 | $5.0B | 45.37% | |
| 71 | —Medgenics, Inc. | 880,539 | $4.9B | 44.51% | |
| 72 | —Akari Therapeutics plc | 496,901 | $4.2B | 38.38% | |
| 73 | NERVGBPMinerva Neurosciences, Inc. | 258,805 | $3.7B | 33.15% | |
| 74 | —Stemline Therapeutics, Inc. | 333,497 | $3.6B | 32.78% | |
| 75 | —Loxo Oncology, Inc. | 137,735 | $3.6B | 32.72% | |
| 76 | —Ignyta, Inc. | 571,000 | $3.6B | 32.60% | |
| 77 | —Array BioPharma Inc. Notes 3.0% 6/1/2020 | 3,000,000 | $3.6B | 32.31% | |
| 78 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $3.2B | 29.41% | |
| 79 | CNCEEURConcert Pharmaceuticals, Inc. | 316,976 | $3.2B | 29.08% | |
| 80 | —Trevena, Inc. | 450,000 | $3.0B | 27.57% | |
| 81 | —Syros Pharmaceuticals, Inc. | 204,465 | $2.8B | 25.74% | |
| 82 | —Adamas Pharmaceuticals, Inc. | 172,630 | $2.8B | 25.71% | |
| 83 | —Proteon Therapeutics, Inc. | 298,591 | $2.8B | 25.28% | |
| 84 | GLYCEURGlycoMimetics, Inc. | 381,235 | $2.7B | 24.74% | |
| 85 | —InVivo Therapeutics Holdings Corp. | 400,000 | $2.7B | 24.68% | |
| 86 | —Endocyte, Inc. | 868,983 | $2.7B | 24.36% | |
| 87 | AGLEUSDAeglea BioTherapeutics, Inc. | 404,230 | $2.6B | 23.51% | |
| 88 | SELBUSDSelecta Biosciences, Inc. | 178,950 | $2.5B | 23.14% | |
| 89 | —Osiris Therapeutics, Inc. | 499,193 | $2.5B | 22.47% | |
| 90 | —Nabriva Therapeutics AG | 350,000 | $2.5B | 22.40% | |
| 91 | —Juno Therapeutics, Inc. | 80,000 | $2.4B | 21.79% | |
| 92 | —Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18 | 3,423,000 | $2.3B | 20.82% | |
| 93 | —Epizyme, Inc. | 232,481 | $2.3B | 20.76% | |
| 94 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.1B | 19.16% | |
| 95 | ISIIonis Pharmaceuticals, Inc. | 57,140 | $2.1B | 19.00% | |
| 96 | ENTAEnanta Pharmaceuticals, Inc. | 75,357 | $2.0B | 18.19% | |
| 97 | SCYXEURSCYNEXIS, Inc. | 467,600 | $1.8B | 16.42% | |
| 98 | ASMBAssembly Biosciences, Inc. | 250,000 | $1.8B | 16.36% | |
| 99 | QUREuniQure N.V. | 230,000 | $1.8B | 15.97% | |
| 100 | —MediWound Ltd. | 226,000 | $1.7B | 15.79% |
Page 1 of 2Next